Insulet PODD International — Total Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Insulet in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The official record: Insulet’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Insulet's international — total revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Insulet's international — total revenue?
- Insulet (PODD) reported international — total revenue of $242.9M in Q1 2026.
- How has Insulet's international — total revenue changed year-over-year?
- Insulet's international — total revenue increased by 59.5% year-over-year, from $152.3M to $242.9M.
- What is the long-term trend for Insulet's international — total revenue?
- Over 4 years (2021 to 2025), Insulet's international — total revenue has grown at a 20.3% compound annual growth rate (CAGR), from $359.9M to $754.3M.
- What does international — total revenue mean?
- Total revenue earned from the international sales of the company's primary insulin delivery product line.
- How do you interpret international — total revenue?
- Growth in this metric suggests strong international demand and effective global commercialization strategies for the core product.
- How does international — total revenue compare across companies?
- Similar to product-specific geographic revenue disclosures found in the financial reports of global health technology and medical device companies.